Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2009.08.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.
Biomedicines
December 2021
Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats. If not upgraded, one episcleral vein is regularly unable to acquire and take over the whole function, and glaucoma-like features persist. Recently, the rapid upgrading of the collateral pathways by a stable gastric pentadecapeptide BPC 157 has cured many severe syndromes induced by permanent occlusion of major vessels, veins and/or arteries, peripherally and centrally.
View Article and Find Full Text PDFChemo-informatics guided study of natural inhibitors targeting rho GTPase: a lead for treatment of glaucoma.
In Silico Pharmacol
January 2021
Department of Biotechnology, Govind Ballabh Pant Institute of Engineering and Technology, Pauri Garhwal, Uttarakhand 246194 India.
Glaucoma, the most perilous disease leading to blindness is a result of optical neuropathy. Accumulation of aqueous humor in the posterior chamber due to a large difference in the rate of formation and its drainage in the anterior chamber causes an increase in intraocular pressure (IOP) leading to damage of nerve cells. A literature survey has revealed that inhibition of the Rho guanosine triphosphatases (rho GTPase) pathway by specific inhibitors leads to the relaxation of contractile cells involved in the aqueous outflow pathway.
View Article and Find Full Text PDFGlaucoma: an emerging peril.
Indian J Community Med
July 2013
Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribing.
BMJ Case Rep
April 2013
Department of Dermatology, St Louis University, St Louis, Missouri, USA.
We report three patients with superficial haemangiomas treated topically with Combigan ophthalmic solution (brimonidine 0.2%-timolol 0.5%), a combination selective α-2-adrenergic agonist and non-selective β-blocker Food and Drug Administration-approved for use in glaucoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!